ArticleJournal of personalized medicine2013
Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information.
Article in Journal of personalized medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.PloS one · 2022Article
- Physicians' Knowledge and Attitudes Regarding Point-of-Care Pharmacogenetic Testing: A Hospital-Based Cross-Sectional Study.Pharmacogenomics and personalized medicine · 2021Article
- Biomarker and Companion Diagnostics-A Review of Medicinal Products Approved by the European Medicines Agency.Frontiers in medicine · 2021Article
- Landmarks of pharmacogenomics and some considerations for clinical practice.Therapeutic advances in psychopharmacology · 2019Article
- Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository.Clinical pharmacology and therapeutics · 2017Article
- Clinician Perspectives on Using Pharmacogenomics in Clinical Practice.Personalized medicine · 2015Article
- Ethical issues in pediatric pharmacogenomics.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We surveyed 10,303 United States physicians on where they obtain pharmacogenomic testing information. Thirty-nine percent indicated that they obtained this from drug labeling. Factors positively associated with this response included older age, postgraduate instruction, using other information sources, regulatory approval/ recommendation of testing, reliance on labeling for information, and perception that patients have benefited from testing. Physicians use pharmacogenomic testing information from drug labeling, highlighting the importance of labeling information that is conducive to practice application.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.